Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AGIO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Mitapivat (AG-348) FDA approved Feb 2022 · Pyrukynd |
Pyruvate Kinase Deficiency | Phase 4 · NCT05777993 | Enrolling by invitation |
| AG-236 | Polycythemia Vera | Phase 2/3 · NCT07859423 | Not yet recruiting |
| Tebapivat (AG-946) | Myelodysplastic Syndromes | Phase 2 · NCT05490446 | Active not recruiting |
| Enasidenib | Hematologic Neoplasms | Phase 1/2 · NCT01915498 | Completed |
| Ivosidenib (AG-120) | Chondrosarcoma | Phase 2 · NCT04278781 | Active not recruiting |
| [13C2,15N3]-tebapivat | Healthy Participants | Phase 1 · NCT06745271 | Completed |
| Vorasidenib (AG881) | Healthy Volunteers | Phase 1 · NCT04128787 | Completed |
| Dihydroorotate Dehydrogenase Inhibitor AG-636 | Lymphoma | Phase 1 · NCT03834584 | Terminated |
| AG-181 | Phenylketonuria | Phase 1 · NCT07241234 | Recruiting |
| [14C]-tebapivat | Healthy Participants | Phase 1 · NCT06745271 | Completed |
| [13C6]AG-348 | Healthy Volunteers | Phase 1 · NCT03703505 | Completed |
| [13C315N3]AG-881 | Healthy Male Participants | Phase 1 · NCT03960502 | Completed |
Also used in these trials (approved or third-party drugs, not AGIO's own candidates): Omeprazole, Rifampin, Midazolam Hydrochloride, Lamotrigine, Itraconazole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AGIO holds $907M in cash and short-term investments (as of Sep 30, 2026) and burns about $58.3M/quarter from operations, an estimated runway of 46.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AGIO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 6,229,199 | 10.42% | 2026-09-30 |
| Farallon Capital Management LLC | Institution (13F) | 5,939,400 | 9.93% | 2026-09-30 |
| Farallon Capital Management, L.L.C. | Institution (13G, 5%+) | 5,917,400 | 9.89% | 2026-06-30 |
| Dapice Joshua J. | 5%+ holder (13G) | 5,159,505 | 8.63% | 2025-12-31 |
| D. E. Shaw & Co., L.P. | Institution (13G, 5%+) | 3,888,907 | 6.50% | 2026-09-30 |
| Morgan Stanley | Institution (13G, 5%+) | 3,431,830 | 5.74% | 2026-09-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 3,108,145 | 5.20% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 3,088,169 | 5.16% | 2026-03-31 |
| Vanguard Portfolio Management LLC | Institution (13F) | 2,850,204 | 4.77% | 2026-09-30 |
| Armistice Capital, LLC | Institution (13F) | 2,578,000 | 4.31% | 2026-09-30 |
| Assenagon Asset Management S.A. | Institution (13F) | 1,886,412 | 3.15% | 2026-09-30 |
| Brian Goff Chief Executive Officer, Director · +394,500 options |
Insider | 184,508 | 0.31% | 2026-04-02 |
Share count 59,809,651 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-26 filed 2026-10-28 |
Gheuens Sarah |
Option exercise (M) | 7,866 | $25.01 | 62,511 |
| 2026-10-26 filed 2026-10-28 |
Gheuens Sarah |
Sale (S) | 7,866 | $37.69 | 54,645 |
| 2026-10-26 filed 2026-10-28 |
Gheuens Sarah |
Option exercise (M) | 7,866 | – | – |
| 2026-10-22 filed 2026-10-23 |
Gheuens Sarah |
Option exercise (M) | 500 | $25.01 | 55,145 |
| 2026-10-22 filed 2026-10-23 |
Gheuens Sarah |
Sale (S) | 500 | $37.52 | 54,645 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-12-07 | AQVESME | sNDA | -31.6% | -1.6% | -1.7% |
| 2025-09-07 | PYRUKYND | sNDA | -4.5% | +1.1% | +2.1% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AGIO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →